Sun Pharmaceutical Industries Ltd on Tuesday announced the launch of Favipiravir for the treatment of mild to moderate cases of Covid-19 in India.

The tablet launched under brand name FluGuard costs Rs 35 per tablet.

Favipiravir is an oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate Covid-19 disease.

The stocks of FluGuard will be available in the market from this week, Sun Pharma said.

“With over 50,000 Covid-19 cases being reported daily in India, there is an urgent need to provide more treatment options to healthcare professionals,” Kirti Ganorkar, CEO of India Business, Sun Pharma, said in a statement.

“We are launching FluGuard at an economical price to make the drug accessible to more and more patients, thereby reducing their financial burden. This is in line with our continuous efforts to support India’s pandemic response,” the statement further said.

Avatar photo


Northeast Now is a multi-app based hyper-regional bilingual news portal. Mail us at: